INTRODUCTION
Influenza A is an important pathogen in allogeneic hematopoietic stem cell transplantation (HSCT) recipients, with reported rates of pneumonia of 29%-80% and case fatality rates of 10%-25% [1] [2] [3] [4] [5] [6] [7] . In April 2009, a novel H1N1 influenza A virus of swine origin was identified in Mexico and spread rapidly throughout the world, reaching pandemic levels. Given that the 2009 H1N1 virus continues to circulate globally, and the fact that the 2009 H1N1 antigen will be a component of the standard influenza vaccination moving forward, we investigated the safety and serologic titers to the monovalent 2009 H1N1 vaccination in allogeneic HSCT recipients at our institution, and examined factors associated with the serologic response in this population.
MATERIALS AND METHODS
Outpatient allogeneic HSCT recipients at our institution who received unadjuvanted 2009 H1N1 vaccine ( oseltamivir, results of any diagnostic testing for influenza infection between April 2009 and blood collection time, and any adverse events potentially associated with H1N1 vaccination, were recorded. Anti-influenza antibody titers were measured by Focus Diagnostics (Cypress, CA) using a standard hemagglutination inhibition (HAI) assay [8] . All specimens were tested in triplicate against H1N1: A3/California/7/ 2009, H1N1: A1/Brisbane/59/2007, H3N2: A2/ Brisbane/10/2007, and B strain: B/Brisbane/60/2008. The primary immunogenicity endpoint was the proportion of subjects with a geometric mean antibody titer of $1:40, which is the typical minimum titer associated with protection as defined by the Centers for Disease Control and Prevention and the Food and Drug Administration [8] . Logistic regression was used for univariate and multivariate analyses. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
Serum samples from 82 allogeneic HSCT recipients who returned to clinic following receipt of the 2009 H1N1 vaccination during the study period were available for analysis. Clinical characteristics are summarized in Table 1 . Two additional patients had documented H1N1 influenza before vaccination and were excluded from the analysis; both had high HAI titers. Patients received the vaccination and returned for follow-up at the discretion of the treating physician. The median patient age at the time of vaccination was 55 years (range, 20-71 years). The median time between HSCT to vaccination was 578 days (interquartile range [IQR] , 358-879 days; range, 77-2819 days), and the median time between vaccination and specimen collection was 56 days (range, 14-140 days). The median donor age was 40 years (IQR, 30-47 years; range, 23-65 years). Forty-one patients had chronic GVHD at time of vaccination, and two patients had acute GVHD. Sixty-one patients were receiving an immunosuppressive medication at time of vaccination. Thirty-two patients had received the 2009 seasonal influenza vaccine.
Seroprotective titers (HAI titer $1:40) against 2009 H1N1 influenza A virus were detected in 51.2% of the patients (Table 1 ). Figure 1 Table 2 . Of note, no patient studied underwent T celldepleted transplantation. In the year before vaccination, rituximab was administered to 7 patients as part of a clinical trial for chronic GVHD prophylaxis and to 4 patients who received rituximab to treat chronic GVHD. Rituximab therapy (375 mg/m 2 ) in the year preceding vaccination was associated with a significantly diminished rate of seroprotective titers to the 2009 H1N1 vaccination (9.1%; adjusted odds ratio [OR], 0.11; 95% confidence interval [CI], 0.01-0.97; P 5 .04). Patients who received mycophenolate mofetil (MMF) therapy had a lower rate of seroprotective titers compared with those who did not receive MMF (33.3% vs 56.2%); however, the difference was not statistically significant (P 5 .11). Seroprotective titer rates were higher in patients with longer intervals between HSCT and vaccination (adjusted OR, 1.79 per year after HSCT; 95% CI, 1.12-2.85; P 5 .01). The rate of seroprotection was 37% in patients who received the 2009 H1N1 vaccine less than 6 months after HSCT, 50.0% in those who did so between 6 months and 1 year after HSCT, 38.7% in those who did so between 1 and 2 years after HSCT, 69% in those who did so more than 2 years after HSCT. The 2009 H1N1 vaccine was safe and well tolerated; no significant vaccine associated adverse events were noted. No patient had confirmed H1N1 influenza infection from the time of vaccination to the time of specimen collection.
DISCUSSION
The serologic response rate to the seasonal influenza vaccine and the clinical efficacy of vaccination are reportedly influenced by various factors, including age, timing of vaccination after HSCT, GVHD, and exposure to immunosuppressant medications (eg, steroids, rituximab, alemtuzumab) [9] [10] [11] [12] [13] [14] . A poor serologic response to vaccine antigens has been documented in HSCT recipients receiving seasonal influenza vaccination within the first 6 months after HSCT [11] . A comparison of humoral and cellular immune responses to influenza vaccination in HSCT recipients and healthy volunteers revealed that overall, the HSCT recipients had a lower protective humoral response to the vaccination, with a particularly diminished response seen in those vaccinated within the first 6 months after transplantation; however, the vaccine still elicited a strong T cell-mediated immune response in both groups [10, 15] . We found a 37% rate of seroprotection in the patients who received 2009 H1N1 vaccination less than 6 months after HSCT; it difficult to discern the overall vaccine immune response to these antigens versus possible previous seasonal influenza infection. Overall, seroprotection against all of the influenza viruses observed was modest, even in patients who received the trivalent vaccine, with particularly low titers to influenza B, consistent with previous reports [16, 17] .
In our study cohort, the overall rate of seroprotection after 2009 H1N1 vaccination was modest (51.2%) compared with the rate of 96.7% (95% CI, 91.7%-98.7%) observed in the general population [8] . Historically, the response rate to seasonal influenza vaccination in HSCT recipients has been found to be blunted compared with healthy individuals (29%-34% vs 46%-62%) [12] . Rituximab therapy initiated within 1 year of vaccination was significantly associated with a decreased rate of seroprotective titers. This finding might be attributed to the prolonged depletion of B lymphocytes after rituximab administration [18] , or might be related to loss of antigen presentation or B cells' function. A poor response to seasonal influenza vaccination has been reported in patients who received rituximab or alemtuzumab therapy for lymphoma [9] . As reported previously with seasonal influenza vaccination [11] , a longer interval between HSCT and influenza vaccination is correlated with better serologic response to the 2009 H1N1 influenza vaccination, with an increasing OR of 1.79 (95% CI, 1.12-2.85) per year after HSCT for achieving a seroprotective level. Importantly, the presence of chronic GVHD, concurrent immunosuppressive therapy (including prednisone), and the type of conditioning regimen did not influence the rate of seroprotection against 2009 H1N1 influenza virus in our cohort. Previous studies found lower titers in patients with GVHD and patients who received more intensive conditioning regimens [11, 14] ; although these observations are plausible, the small number of patients makes the data less reliable.
Although our analysis lacks baseline 2009 H1N1 antibody titers because it was carried out in an epidemic setting, with vaccinations administered as they became available, it is highly unlikely that our findings were affected by preexisting immunity to H1N1 from infection. Such an effect would lead to an overestimation of the seroprotective titer rate. Preexisting antibody titers against 2009 H1N1 influenza A virus in up to 34% of individuals born before 1950 have been reported [19] ; however, our data show no difference in the seroprotective titer rate between patients or donors older and younger than age 60. We also found no difference in the seroprotective titer rate between patients with and without an influenza-like illness, patients with and without oseltamivir therapy, and patients with and without seasonal influenza vaccination. In 2 recent studies, vaccination with seasonal nonadjuvanted or adjuvanted influenza vaccines induced little or no cross-reactive antibody response to 2009 H1N1 in any age group [19, 20] . The 2009 H1N1 vaccine proved safe and well tolerated, with no significant vaccine-associated adverse events noted, in agreement with another study [21] .
In summary, we found a modest rate of seroprotective titers against 2009 H1N1 influenza virus in our cohort of allogeneic HSCT recipients. Based on these data, administration of influenza vaccination relatively early after transplantation should be considered in all HSCT recipients. Given the modest response rate, strategies to improve influenza vaccine response are needed, and patients should continue to use protective measures to prevent viral respiratory infections. These data further demonstrate the impact of rituximab on the response to the influenza vaccine and may have implications for the response to other vaccines as well.
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